Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djae338 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Ann Oluloro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, United States. Hauptthemen laut MEDLINE: Patient Selection, Clinical Trials as Topic, Genital Neoplasms, Female, Eligibility Determination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institute of Health, National Cancer Institute.
Abstract (Originalsprache)
Background
Racial and ethnic minorities remain underrepresented in gynecologic cancer clinical trials despite disproportionately worse oncologic outcomes. Research shows differential racial enrollment patterns because of comorbidity-based exclusion criteria. Our objective was to evaluate contemporary trends in comorbidity-based exclusion criteria among National Cancer Institute–sponsored gynecologic cancer clinical trials and protocol adherence to broadened eligibility criteria guidelines as an assessment of equitable enrollment access.
Methods
The ClinicalTrials.gov registry was queried for National Cancer Institute–sponsored gynecologic cancer clinical trials (1994-2021). Study characteristics and comorbidity-based exclusion criteria were abstracted from protocols. Descriptive statistics and temporal trends were calculated using χ2 testing with STATA v17 software.
Results
Among 279 clinical trials identified, 65% completed enrollment, 53% were phase II, and 48% focused on ovarian cancer. Pharmaceutical agents (85%) were the primary therapeutic interventions. Several inequitably restrictive exclusion criteria increased over time such as hepatitis infection (17% in 1994-2000 vs 49% in 2015-2021, P < .001) and cardiovascular disease (47% in 1994-2000 vs 66% in 2015-2021, P = .002). A previously rare exclusion, “mental illness and/or social situations,” dramatically increased from 5% to 51% (P < .001) over 3 decades. Adherence to broadened eligibility criteria recommendations was mixed. Renal function, cardiovascular disease, and performance status criteria were not broadened, but HIV, prior or concurrent malignancies, and brain metastasis criteria were.
Conclusions
Some, but not all, of the known restrictive comorbidity-based exclusion criteria have increased in gynecologic cancer clinical trial design, despite calls for improving racial and ethnic minority representation. Exclusion criteria are critical for trial safety, however, they must be carefully considered given the differential racial impact on eligibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, United States.
ORCID-Profile: Ann Oluloro, Elizabeth M Swisher, Barbara Goff, Kemi M Doll
Förderung
- NCI NIH HHS
- National Institute of Health
- National Cancer Institute
Zitieren
APA
Oluloro, A., Swisher, E. M., Gray, H. J., Goff, B., & Doll, K. M. (2025). Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae338
Vancouver
Oluloro A, Swisher EM, Gray HJ, Goff B, Doll KM. Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae338
BibTeX
@article{Oluloro2025,
author = {Oluloro, Ann and Swisher, Elizabeth M and Gray, Heidi J and Goff, Barbara and Doll, Kemi M},
title = {Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djae338}
}
EUVIMED